相关实验视频

Updated: May 28, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

从海洋化合物库中识别DDR1抑制剂,基于药模型和脚手架跳跃

Honghui Hu¹, Jiahua Tao¹, Lianxiang Luo²

¹The First Clinical College, Guangdong Medical University, Zhanjiang 524023, China.

International journal of molecular sciences

|February 13, 2025

概括

新的DDR1抑制剂对性结肠炎 (UC) 治疗有希望. 研究人员从海洋来源中识别出有力的化合物,改善了类似药物的特性和稳定性,用于潜在的治疗用途.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
药用化学医学化学

背景情况:

性结肠炎 (UC) 是一种慢性肠道炎症疾病.
在UC中,DDR1激酶活性对于维持肠道屏障功能至关重要.
现有的DDR1抑制剂面临毒性和稳定性的挑战,需要开发新药.

研究的目的:

确定用于性结肠炎治疗的新型,有效和更安全的DDR1抑制剂.
为选潜在的DDR1抑制剂开发一个经过验证的药模型.
从海洋天然产品中发现和优化化合物.

主要方法:

对85种DDR1抑制剂进行分析,以构建一个药理分子模型.
在海洋天然产品数据库 (>52,000个化合物) 中进行高通量虚拟选.
对接,脚手架跳跃,ADMET分析和分子动力学模拟用于化合物优化和验证.

主要成果:

从海洋来源鉴定出17种潜在的DDR1抑制剂.
通过脚手架跳跃生成了1070种新型化合物,改善了结合亲和力和类似药物的特性.
与已知的抑制剂相比,选择了三种化合物 (39713a,34346a,34419a) 具有优越的预测活性,稳定的相互作用和有利的ADMET配置文件.

结论:

化合物39713a,34346a和34419a显示出作为DDR1抑制剂的显著潜力.
这些化合物在性结肠炎治疗中表现出有前途的治疗前景,原因是提高了疗效和类似药物的特性.

关键词:

接收人接收人这是一种DDR1抑制剂.这就是HTVS.分子动力学 (MD) 模拟作为一个药物学家,他做了一些药物学.在脚手架上跳跃跳跃.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...